Most Targeted Cancer Drugs Lack Substantial Clinical Benefit Most Targeted Cancer Drugs Lack Substantial Clinical Benefit

Only a minority of genome-targeted cancer drugs recently approved in the United States demonstrate significant clinical benefits to patients, a new analysis found.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology Clinical Summary Source Type: news